Cantargia to present new clinical data on lead IL1RAP antibody nadunolimab over three sessions at ASCO 2022
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) will present three posters with new clinical data from the CANFOUR and CIRIFOUR trials on its most advanced program, nadunolimab, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022 to be held in Chicago on 3-7 June 2022. Two of the presentations will also be included in poster discussion sessions where select posters are highlighted. These focus on therapy of pancreatic cancer (PDAC) or non-small cell lung cancer (NSCLC) patients in the CANFOUR trial.“We are excited to communicate Cantargia’s clinical data updates at